Laura Zeppilli

Laura Zeppilli

Auto-generated profile, based on publicly available information

Laura Zeppilli

Hemodialysis Unit, Department of Internal Medicine and Clinical Sciences, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Sapienza University of Rome, Rome, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2017 in Blood Purification
Verified
Journal Article
Closed access
VPValentina Pistolesi
Valentina Pistolesi
LZLaura Zeppilli
Laura Zeppilli
FPFrancesca Polistena
Francesca Polistena
MSMaria Itala Sacco
Maria Itala Sacco
APAlessandro Pierucci
Alessandro Pierucci
SMSanto Morabito
Santo Morabito
Aims: To evaluate the efficacy and safety of a commercially available phosphate-containing solution for continuous renal replacement therapy (CRRT) in preventing CRRT-related hypophosphatemia. Methods: In heart surgery patients undergoing continuous veno-venous haemodiafiltration (CVVHDF) with regional citrate anticoagulation (RCA), we combined an 18 mmol/l citrate solution with a phosphate-containing (1.2 mmol/l) dialysate/replacement fluid evaluating the incidence of hypophosphatemia and the need for parenteral phosphorus supplementation. Results: In 75 patients on RCA-CVVHDF, the mean filter life was 53.9 ± 33.6 h. Regardless of baseline levels, phosphoremia was progressively corrected and maintained in a narrow normality range throughout RCA-CRRT days (after 72 h: 1.14 ± 0.25 mmol/l). Considering the whole CRRT period, 45 out of 975 (4.6%) serum phosphorus determinations met the criteria for mild (<0.81 mmol/l) or moderate (<0.61 mmol/l) hypophosphatemia; severe hypophosphatemia (<0.32 mmol/l) never occurred. After 72 h 88% of the patients were normophosphatemic, 9% hyperphosphatemic and 3% hypophosphatemic. Conclusions: RCA-CVVHDF with a phosphate-containing solution enabled the maintenance of phosphorus levels within normophosphatemic range in most of the patients, minimizing the occurrence of CRRT-related hypophosphatemia.

7 January 2026 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
LZLaura Zeppilli
Laura Zeppilli
SMSanto Morabito
Santo Morabito
Pasquale EspositoPasquale Esposito
Pasquale Esposito
VPValentina Pistolesi
Valentina Pistolesi

1 May 2026 in Journal Of Nephrology
Verified
Journal Article
Closed access
FMFrancesca Di Mario
Francesca Di Mario
LZLaura Zeppilli
Laura Zeppilli
SMSanto Morabito
Santo Morabito
PTPierfrancesco Tozzi
Pierfrancesco Tozzi
VPValentina Pistolesi
Valentina Pistolesi
Tailoring dialysis prescriptions in critically ill patients with severe acute kidney injury (AKI) represents a significant challenge, requiring a balance between adequate solute clearance and the minimization of treatment-related complications. Recent evidence highlights the potential advantages of a low dialysis dose in limiting electrolyte disturbances, preserving essential nutrients, and reducing the need for pharmacologic interventions, while maintaining effective metabolic control. Regional citrate anticoagulation (RCA), widely considered as the first anticoagulation strategy for Continuous Kidney Replacement Therapy (CKRT), also contributes to dialysis buffer balance through the indirect generation of bicarbonate from citrate metabolism. In this regard, modulation of citrate metabolic load may allow the optimization of acid–base balance without increasing dialysis intensity. Therefore, RCA may represent a versatile tool to individualize CKRT prescriptions, enabling both effective metabolic management and lower dialysis doses, thereby enhancing patient safety and therapeutic efficiency in the intensive care setting.

19 July 2025 in Internal and Emergency Medicine
Verified
Journal Article
Closed access
PDF file
LZLaura Zeppilli
Laura Zeppilli
SMSanto Morabito
Santo Morabito
AGAntonietta Gigante
Antonietta Gigante
VPValentina Pistolesi
Valentina Pistolesi